Systemic lupus erythematosus (SLE) is a prototypic
autoimmune disease of unknown etiology characterized
by diversity of clinical manifestations with
unpredictable course. Vasculitis is an inflammation
of the vessel walls with a broad spectrum of clinical
forms due to its capacity to affect vessels of different
sizes and sites. Its prognosis may range from
mild to life-threatening.1 The prevalence of vasculitis
in large series of SLE patients varies between
11% and 20%.2 Cutaneous vasculitis is common in
SLE, whereas visceral vasculitis is infrequent.